Digest Network Come funziona
Network
/
Società
No
Non verificato

Novo Nordisk A/S

Di cosa scriviamo

FarmaceuticaFinanzaManagement/Organizzazione AziendalePolitica InternazionalePubblicità/Marketing/Media/Comunicazione

94 comunicati stampa

Guarda tutti i comunicati
12/05/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
12/05/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
11/05/2026
Farmaceutica
Medicina Salute Benessere
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
05/05/2026
Farmaceutica
Management/Organizzazione Aziendale
Politica Internazionale
Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
28/04/2026
Farmaceutica
Medicina Salute Benessere
Pubblicità/Marketing/Media/Comunicazione
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
23/04/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
20/04/2026
Farmaceutica
Politica Internazionale
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
13/04/2026
Farmaceutica
Management/Organizzazione Aziendale
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
09/04/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0
26/03/2026
Farmaceutica
Politica Internazionale
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Fonte
Novo Nordisk A/S
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0